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Abstract
Introduction: Cancer patients with chemotherapy-induced febrile neutropenia are a heterogeneous group with a significant risk of serious medical 
complications. In these patients, the Multinational Association for Supportive Care in Cancer (MASCC) score is the most widely used tool for risk-stra-
tification. The aim of this prospective study was to analyse the value of procalcitonin (PCT) and lipopolysaccharide binding protein (LBP) to predict 
serious complications and bacteraemia in cancer patients with febrile neutropenia, compared with MASCC score. 
Materials and methods: Data were collected from 111 episodes of febrile neutropenia admitted consecutively to the emergency department. In 
all of them, MASCC score was calculated and serum samples were collected for measurement of PCT and LBP by well-established methods. The main 
and secondary outcomes were the development of serious complications and bacteraemia, respectively.
Results: A serious complication occurred in 20 (18%) episodes and in 16 (14%) bacteraemia was detected. Areas under the receiver operating cha-
racteristic curve (ROC AUC) of MASCC score, PCT and LBP to select low-risk patients were 0.83 (95% confidence interval (CI): 0.74 - 0.89), 0.85 (95% 
CI: 0.77 - 0.91) and 0.70 (95% CI: 0.61 - 0.78), respectively. For bacteraemia, MASCC score, PCT and LBP showed ROC AUCs of 0.74 (95% CI: 0.64 - 0.82), 
0.86 (95% CI: 0.78 - 0.92) and 0.76 (95% CI: 0.67 - 0.83), respectively.
Conclusion: A single measurement of PCT performs similarly as MASCC score to predict serious medical complications in cancer patients with febrile 
neutropenia and can be a useful tool for risk stratification. Besides, low PCT concentrations can be used to rule-out the presence of bacteraemia. 
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tein
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Febrile neutropenia is a well-known complication 
induced by chemotherapy and one of the most 
frequent oncologic emergencies encountered by 
physicians in an emergency department (1). As this 
condition predisposes to infection and related se-
rious complications, it requires establishing imme-
diately the prognosis and treatment of the patient. 
Besides, because oral or ambulatory treatment is a 
safe alternative to inpatient management, the 
identification of patients being at low risk for com-
plications, candidates for outpatient management, 
is essential to avoid the overtreatment and unnec-
essary hospital admissions (1). 
The most widely used model to identify low-risk 
patients with febrile neutropenia is Multinational 
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Association for Supportive Care in Cancer (MASCC) 
risk index score, based on seven independent pre-
dictive factors that can be assessed at fever onset, 
without laboratory results (2). However, it has also 
limitations: some of its components are objective 
(e.g., patient age), but two components are inher-
ently subjective: burden of disease and presence 
of dehydration requiring iv. fluids. Besides, its abil-
ity to predict serious complications is not optimal, 
because they occur in up to 9% to 15% of episodes 
classified as low-risk (3). Although the use of MAS-
CC risk score has been recommended in the most 
recent international guidelines, Baugh et al. have 
recently concluded that guideline concordance 
was low among low-risk patients, with manage-
ment, including admission to hospital and paren-
teral antibiotic regimens, tending to be more ag-
gressive than recommended (4,5). 
Since the infectious aetiology is the main cause of 
complications in cancer patients with febrile neu-
tropenia, several studies have evaluated the role 
of infection biomarkers, such as procalcitonin 
(PCT), to improve the performance of MASCC 
score for risk-stratification or have included it in 
new prognostic models (6,7). Less known is the 
prognostic role of another infection biomarker, li-
popolysaccharide binding protein (LBP), which has 
a diagnostic accuracy for infection similar to PCT, 
recently reported by our group in a previous co-
hort including febrile neutropenia episodes pre-
senting to the emergency department of our hos-
pital from 2010 to 2012 (8).
The purpose of this prospective diagnostic accu-
racy study was to evaluate the value of PCT and 
LBP, measured in the first blood collected at the 
emergency department, as predictors of serious 
complications and bacteraemia during an episode 
of febrile neutropenia in cancer patients, com-
pared with MASCC score. 
Materials and methods
Study design and subjects
From November 2012 to June 2014, a single-center 
prospective observational cohort study was per-
formed at the emergency department (ED) of the 
University Hospital Santa Lucía (Cartagena, Spain). 
Inclusion criteria were adult (≥ 18 years) outpa-
tients with febrile neutropenia who received 
chemotherapy for underlying malignancy within 5 
weeks prior to admission to the emergency de-
partment. Patients previously treated at other hos-
pitals for neutropenic episodes and then trans-
ferred to our hospital were excluded. Neutropenia 
was defined as a neutrophil count of < 0.5 x109/L, 
or < 1.0 x109/L with a predicted decrease to < 0.5 
x109/L. Fever was defined as a single oral tempera-
ture of ≥ 38.3 °C or ≥ 38 °C for ≥ 1 hour (9). In our 
hospital, cancer patients with fever are initially 
evaluated by emergency physicians. After con-
firming the presence of neutropenia, an expert cli-
nician in Hematology (for haematological malig-
nancies) or Oncology/Internal Medicine (for solid 
tumours) re-evaluated the patients and MASCC 
score was calculated and recorded in the patient s´ 
clinical history.
The study was performed according to the Decla-
ration of Helsinki and approved by the Ethics Com-
mittee for Clinical Research at our hospital 
(TI11/14). Written informed consent was obtained 
from all patients. 
Demographic and clinical data, such as type of 
cancer, focus of infection, fever duration, MASCC 
score on admission to emergency department 
and hemodynamic and biochemical and coagula-
tion tests suggestive of organ dysfunction, were 
collected from the medical records. 
Outcomes
The main outcome was the development of seri-
ous complications after the initial screening and 
until febrile neutropenia resolution, with modifica-
tions of the initial antibiotic therapy allowed. The 
serious complication outcome was defined as the 
presence of at least one of the following: hypoten-
sion (systolic blood pressure less than 90 mm Hg 
or need for pressor support to maintain blood 
pressure), respiratory failure (arterial oxygen pres-
sure less than 60 mm Hg while breathing room air 
or need for mechanical ventilation), intensive care 
unit admission, disseminated intravascular coagu-
lation, confusion or altered mental status, conges-
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tive cardiac failure seen on chest x-ray and requir-
ing treatment, severe bleeding requiring transfu-
sion, electrocardiogram changes or arrhythmia re-
quiring treatment, renal failure requiring investiga-
tion and/or treatment with intravenous fluids, di-
alysis or any other intervention and any other 
complication judged serious and clinically signifi-
cant by the investigator (2). Mild symptoms, such 
as mild pain, nausea, chills, myalgia or arthralgia, 
were not included in the defined criteria for seri-
ous complication. Besides, we defined bacterae-
mia as a secondary outcome. Although bacterae-
mia cannot be considered as a complication itself, 
it is a relatively common condition in cancer pa-
tients with febrile neutropenia and the occurrence 
of complications and mortality is higher in bacte-
remic episodes; therefore, early prediction of bac-
teraemia in these patients might be important to 
tailor empirical treatment to cover the increased 
risk (10). Bacteraemia was defined as the presence 
of alive bacteria in blood in one or both blood cul-
ture sets. In cases where only one set of microor-
ganisms usually considered as contaminant, such 
as coagulase-negative staphylococci, viridans 
streptococci, Propionobacterium acnes, Corynebac-
terium sp. and Bacillus sp. was detected, the isola-
tion was considered as contamination and there-
fore not defined as bacteraemia (11).
In patients admitted to ward or intensive care unit 
from ED, both outcomes were determined by only 
two clinicians based on the complete patient’s re-
cords, without knowing biomarker concentrations. 
For discharged patients from ED, at the discretion 
of the treating physicians, notes from subsequent 
visits up to 30 days post-discharge were reviewed 
to evaluate for adverse outcomes.
Blood sampling 
Blood samples were collected by venipuncture 
into tubes with separator gel (BD Vacutainer SST II 
Advance 8.5 mL) on presentation to emergency 
department. Samples for PCT and LBP were centri-
fuged at 3000 rpm for 10 minutes. Separated se-
rum was used for the immediate measurement of 
PCT and remaining serum was frozen and stored 
at - 80 °C until LBP measurement was carried out, 
according to the manufacturer s´ recommenda-
tions about LBP stability.
For microbiological investigations, collection of bi-
ological samples was ordered by physicians in the 
ED. According to the procedures of ED in our hos-
pital, blood culture was required in all the epi-
sodes. Blood for culture was collected in two sets 
of bottles (BACTEC plus Aerobic/F, Becton Dickin-
son Microbiology Systems, Cokeysville, USA), one 
aerobic and one anaerobic, prior to initiation of 
antibiotic therapy, and incubated for at least 5 
days (BD BACTEC FXâ system, Becton Dickinson 
Microbiology Systems, Cokeysville, USA). All iso-
lates were identificated following standard proce-
dures (Microscanâ WalkAway system, Siemens 
Healthcare Diagnostics, Los Angeles, USA). Be-
sides, cultures from other origins, such as urine, 
respiratory tract, cerebrospinal fluid, stool, or 
wound exudates, were collected according to the 
clinical judgement of treating clinicians, according 
to the standard procedures of Microbiology and 
Parasitology Department. 
Methods 
Serum PCT concentrations were measured on a 
Cobas e411 analyser (Roche Diagnostic, Mannhe-
im, Germany) by an electrochemiluminiscence as-
say. According to manufacturer s´ data, detection 
limit, functional sensitivity and measurement 
range were 0.02 mg/L, 0.06 mg/L and 0.02 to 100 
mg/L, respectively, and the total imprecision, ex-
pressed as coefficient of variation (CV), ranged 
from 0.9% for a mean level of 10.2 mg/L to 1.3% 
for a mean level of 0.52 mg/L.
Concentrations of LBP were measured with a 
chemiluminescent assay on an Immulite 2000 ana-
lyser (Siemens Healthcare Diagnostics, Los Ange-
les, USA). According to the manufacturer s´ litera-
ture, detection limit, functional sensitivity and 
measurement range were 1.2 mg/L, 1.5 mg/L and 
1.2 to 170 mg/L, respectively, and the total CV 
ranged from 4.1% for a mean level of 107 mg/L  to 
6.0% for a mean level of 5.31 mg/L.
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Statistical analysis
The Kolmogorov-Smirnov and Shapiro-Wilks tests 
were used to assess the normality of distribution 
of investigated parameters. All continuous varia-
bles in our study were distributed non-normally. 
They were presented as medians (interquartile 
range, IQR) and compared with Mann-Whitney 
test. Categorical variables were expressed as fre-
quencies and percentages and compared with 
Chi-square test. To evaluate the discrimination 
ability of the tested variables, area under the re-
ceiver operating characteristic curve (ROC AUC) 
were calculated and differences among ROC AUCs 
were assessed with the Hanley and Mc Neil test. 
We additionally estimated the optimal ROC curve-
derived cut-offs by the Youden index. A binary lo-
gistic regression analysis was performed to identi-
fy predictors for serious complications and bacte-
raemia, including both MASCC score and bio-
chemical markers. The values P < 0.05 were con-
sidered statistically significant. Software packages 
SPSS version 20 (SPSS Inc., Chicago, USA) and Med-
Calc v.15.0 (MedCalc Software, Ostend, Belgium) 
were used for statistical analyses.  
Results
During the study period, 114 consecutive episodes 
of chemotherapy associated febrile neutropenia 
were documented in 105 patients. Three episodes 
in 3 patients were excluded due to the lack of 
blood sample for biomarker measurements. Final-
ly, the population study included 111 episodes of 
febrile neutropenia in 102 patients, with a median 
age of 63 years (range: 21 - 85), and 40 (39%) men 
and 62 women (61%). From that number, 81 had a 
solid tumour (80%), including breast tumour (N = 
36; 44%), lung tumour (N = 22; 27%), gynaecologic 
tumours (N = 8; 10%), urologic tumours (N = 9; 
11%), digestive tumours (N = 4; 5%) and other tu-
mours (N = 2; 3%); and 21 (20%) had haematologi-
cal malignancies, including Hodgkin and non-
Hodgkin lymphoma (N = 16; 76%) and acute leu-
kaemia and myelodysplastic syndromes (N = 5; 
24%). Characteristics of febrile neutropenia epi-
sodes (N = 111) are listed in Table 1. Most of the ep-
isodes, 87 (78%), were classified as having a low 
risk of complication (MASCC risk index score ≥ 21). 
Infection was documented in 57 episodes (51%). 







N = 20 P 
Age (years) 63 (21 - 85) 62 (28 - 85) 70 (21 - 83) 0.105
Male gender, N (%) 42 (38) 28 (31) 14 (70) 0.001










MASCC score 24 (21 - 24) 24 (22 - 24) 19 (12 - 22) < 0.001
Low-risk (MASCC index risk score ≥ 21), N (%)






13 (65) < 0.001
Fever duration before admission < 24 h, N (%) 74 (71)* 63 (69) 11 (55) 0.411
Granulocyte-stimulating factors, N (%) 99 (89) 81 (89) 18 (90) 0.897
Age is presented as median (range). MASCC - Multinational Association for Supportive Care in Cancer. MASCC score is presented 
as median (interquartile range). Continuous variables were compared by using Mann-Whitney test. Categorical variables were 
compared by using Chi-square test. *Data available in 105 febrile neutropenia episodes. Fever duration before admission refers to 
the time from the onset of fever to admission to the emergency department. Granulocyte-stimulating factors refers to the onset 
of therapy with granulocyte-stimulating factors when febrile neutropenia was detected. P < 0.05 was considered statistically 
significant.
Table 1. Baseline characteristics of febrile neutropenia episodes
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MASCC score PCT (mg/L) LBP (mg/L)
Non serious complications 24 (22 - 24) 0.13 (0.08 - 0.30) 21.4 (16.2 - 31.4)
Serious complications 19 (12 - 22) 1.02 (0.28 - 11.41) 39.1 (20.8 - 48.9)
P < 0.001 < 0.001 0.005
Non bacteraemia 22 (22 - 24) 0.13 (0.09 - 0.32) 21.4 (16.2 - 33.2)
Bacteraemia 19 (13 - 24) 0.91 (0.40 - 11.41) 44.2 (22.3 - 69.5)
P 0.002 < 0.001 0.001
Data are expressed as median (interquartile range). Continuous variables were compared by using Mann-Whitney test. MASCC - 
Multinational Association for Supportive Care in Cancer. PCT – procalcitonin. LBP - lipopolysaccharide binding protein. P < 0.05 was 
considered statistically significant.
Table 2. Comparison of MASCC risk index score and biomarker concentration
nary (N = 20; 35%) and respiratory tracts (N = 15; 
26%). In patients in whom infection was clinically 
or microbiologically documented no differences 
on biomarker levels were found according to the 
focus of infection. Serious complications were ob-
served in 20 episodes (18%), including 10 deaths 
(9%), and 16 (14%) had positive blood cultures, 14 
Figure 1. Median (boxplots) values of MASCC score, PCT and LBP in patients developing serious complications (up) and bacteraemia 
(down) outcomes. In boxplots, the dark line inside the box is the median of the distribution. The bottom and the top of the boxes 
represent the 1st and the 3rd quartiles and the whiskers represent the intervals containing those values whose distance up to the 1st 
quartile and from the 3rd quartile is smaller or equal to 1.5 times the interquartile range (IQR). MASCC - Multinational Association for 
Supportive Care in Cancer. PCT – procalcitonin. LBP - lipopolysaccharide binding protein.
(88%) by gram-negative bacteria. The occurrence 
of serious complications was higher in bacterae-
mia episodes (43.8% vs. 13.7%; P = 0.004).
Febrile neutropenia episodes developing serious 
complications only differed in gender, MASCC 
score and biomarker levels (Tables 1 and 2, Figure 














































































P < 0.001 P < 0.001 P = 0.005
P = 0.002 P < 0.001 P = 0.001
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1). Concentrations of PCT and LBP were also signif-
icantly higher in the group of bacteraemia epi-
sodes (Figure 1, Table 2). MASCC score was signifi-
cantly lower in episodes with bacteraemia (Figure 
1, Table 2). 
Regarding to the performance of MASCC score 
and biomarker levels as predictor tools (Figure 2), 
MASCC score and PCT concentrations, measured 
at presentation to the ED, showed a similar and 
good ability to predict the development of serious 
complications, with ROC AUCs of 0.83 (95% confi-
dence interval (CI): 0.74 - 0.89) and 0.85 (95% CI: 
0.77 - 0.91), respectively, both higher than LBP 
(ROC AUC: 0.70 (95% CI: 0.61 - 0.78), although the 
difference was marginally significant (P = 0.054) 
when ROC AUCs of MASCC score and LBP were 
compared (Table 3). The combination of MASCC 
score and PCT did not improve the performance of 
both variables alone. Analysing the episodes that 
finally developed a serious complication, 7 and 5 
episodes were classified as low-risk according to 
MASCC score (≥ 21) and PCT concentration (< 0.43 
µg/L), respectively. Four episodes developing a se-
rious complication showed simultaneously a PCT 
< 0.43 µg/L and MASCC score ≥ 21.   
Figure 2. Area under the curve of receiver operating characteristic (with the 95% confidence interval (CI) for the prediction of serious 
complications (A) and bacteraemia (B). MASCC - Multinational Association for Supportive Care in Cancer. PCT – procalcitonin. LBP - 
lipopolysaccharide binding protein.
ROC AUC (95% CI) P P-value of comparison vs. MASCC score
P-value of comparison vs. 
PCT
MASCC 0.83 (0.74 - 0.89) < 0.001 - 0.573
PCT 0.85 (0.77 - 0.91) < 0.001 0.573 -
LBP 0.70 (0.61 - 0.78) 0.005 0.054 0.020
MASCC + PCT 0.84 (0.76 - 0.90) < 0.001 0.526 0.789
MASCC + LBP 0.85 (0.77 - 0.91) < 0.001 0.237 0.972
ROC AUC - Area under the receiver operating characteristic curve. CI - confidence interval. MASCC - Multinational Association for 
Supportive Care in Cancer. PCT – procalcitonin. LBP - lipopolysaccharide binding protein (LBP). Hanley and Mc Neil test was used for 
comparison of ROC AUCs. P < 0.05 was considered statistically significant.
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ROC AUC (95% CI) P P - value of comparison vs. MASCC score
P - value of comparison 
vs. PCT
MASCC 0.74 (0.64 - 0.82) 0.002 - 0.030
PCT 0.86 (0.78 - 0.92) < 0.001 0.030 -
LBP 0.76 (0.67 - 0.83) < 0.001 0.792 0.144
MASCC + PCT 0.80 (0.71 - 0.87) < 0.001 0.010 0.207
MASCC + LBP 0.82 (0.74 - 0.89) < 0.001 0.081 0.428
ROC AUC - Area under the receiver operating characteristic curve. CI - confidence interval. MASCC - Multinational Association for 
Supportive Care in Cancer. PCT – procalcitonin. LBP - lipopolysaccharide binding protein (LBP). Hanley and Mc Neil test was used 
for comparison of ROC AUCs. P < 0.05 was considered statistically significant.
Table 4. Area under the receiver operating characteristic curve of MASCC score and biomarkers to predict bacteraemia
For bacteraemia, ROC AUC corresponding to PCT 
(0.86, 95% CI: 0.78 - 0.92) was higher than those of 
MASCC score (0.74, 95% CI: 0.64 - 0.82) and LBP 
(0.76, 95% CI: 0.67 - 0.83), although when both bio-
markers were compared the difference was not 
significant (P = 0.144) (Figure 2, Table 4). Although 
the combination of MASCC score and PCT in-
creased significantly, the performance of MASCC 
score alone (0.80, 95% CI: 0.71 - 0.87 vs. 0.74, 95% 
CI: 0.64 - 0.82; P = 0.010), it did not improve the 
performance of PCT alone (Table 4). The selected 
cut-offs for MASCC, PCT and LBP and their accura-
cy to predict the development of serious compli-
cations and bacteraemia are listed in Table 5. 
The unadjusted odd ratio (OR) for the develop-
ment of serious complications in episodes with 
MASCC < 21, PCT ≥ 0.43 mg/L and LBP ≥ 28.8 mg/L 
are listed in Table 6. After adjusting for male gen-
der and haematological malignancy, PCT ≥ 0.43 
mg/L showed the strongest independent associa-
tion with the risk of development of serious com-
plications (OR: 10.4, 95% CI: 2.6 - 42.6; P = 0.001) 
(Table 6). For bacteraemia, in multivariate analysis, 
PCT ≥ 0.34 mg/L was the only independent pre-
dictor of this outcome (OR: 10.1, 95% CI: 1.9 - 54.8; 
P = 0.008) (Table 6).
Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Serious complications
MASCC score < 21 75 (51 - 91) 86 (77 - 92) 53 (34 - 73) 94 (86 - 98)
PCT (mg/L) ≥ 0.43 75 (51 - 91) 86 (77 - 92) 54 (34 - 73) 94 (86 - 98)
LBP (mg/L) ≥ 28.8 70 (46 - 88) 73 (62 - 81) 36 (21 - 53) 92 (83 - 97)
Bacteraemia
MASCC score < 21 56 (30 - 80) 80 (71 - 88) 32 (16 - 53) 92 (83 - 97)
PCT (mg/L) ≥ 0.34 81 (54 - 96) 80 (71 - 88) 41 (24 - 60) 96 (89 - 99)
LBP (mg/L) ≥ 40.7 56 (30 - 80) 86 (78 - 93) 41 (20 - 64) 92 (84 - 97)
The cut-offs for PCT and LBP were chosen according to Youden index. 95% confidence intervals are presented in brackets. PPV - 
positive predictive value. NPV - negative predictive value. MASCC - Multinational Association for Supportive Care in Cancer. PCT – 
procalcitonin. LBP - lipopolysaccharide-binding protein.
Table 5. Performance of MASCC risk index score and biomarker levels to predict serious complications and bacteraemia
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Discussion
Febrile neutropenia is one of the most common 
oncological emergencies and the availability of 
objective criteria for an early risk identification is a 
critical task for the management of this condition 
(1,4). This study has investigated the role of PCT 
and LBP, compared to MASCC score, as markers for 
prognosis in adult cancer patients with chemo-
therapy-associated febrile neutropenia presenting 
at an ED. The main findings of the present study 
are: (a) PCT and MASCC score performs similarly to 
predict serious complications in cancer patients 
with a febrile neutropenia episode; and (b) for bac-
teraemia, PCT was the variable with a highest pre-
dictive value.
Regarding to the first finding, PCT and MASCC 
score presented a similar performance to predict 
serious complications, with ROC AUCs of 0.85 and 
0.83, respectively, and higher than that of the oth-
er tested biomarker, LBP (ROC AUC: 0.70), with a 
difference between MASCC score and LBP nearly 
to significance (P = 0.054). Besides, PCT, measured 
on admission to the ED, was a strong predictor for 
serious complications, with an OR of 10.4 for con-
centrations ≥ 0.43 mg/L.
For MASCC score, our results are in accordance 
with results of previous studies validating this risk 
index score. In a recent multicenter study per-
formed in three different emergency depart-
ments, Ahn et al. reported a ROC AUC of 0.77 for 
MASCC score to identify low-risk neutropenic fe-
ver patients, with a negative predictive value (NPV) 
of 87.5% to rule-out serious complications, similar 
to that reported by Uys et al. (NPV: 86.4%), slightly 
lower values than that achieved in our study (94%) 
(12,13). A similar performance was recently report-
ed by Ahn et al. using a new model including de-
mographic, clinical variables and PCT, achieving 
ROC AUCs of 0.84 in derivation set and 0.77 in the 
validation set (7). 
Previous studies have analysed the prognostic role 
of biomarkers in febrile neutropenia patients (13-
15). However, the comparison of results reported 
in these studies is limited due to differences in the 
definition of outcomes, having been included in 
some studies events such as bacteraemia, severe 
sepsis and septic shock or treatment failure as ad-
verse events. In studies using the same adverse 
events as Klastersky et al. to define serious compli-
cations, the results reported about the role of PCT 
are controversial (2). Recently, in a haematological 
population, Michel et al. reported a ROC AUC for 
PCT of 0.92, higher than other biological markers, 
such as IL-8 (ROC AUC: 0.81) and C-reactive protein 
(ROC AUC: 0.72), with an optimal cut-off 0.5 mg/L, 
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Serious complications
MASCC score < 21 13.5 (4.4 - 41.2) < 0.001 4.8 (1.2 - 19.0) 0.027
PCT ≥ 0.43 mg/L 18.0 (5.6 - 58.0) < 0.001 10.4 (2.6 - 42.6) 0.001
LBP ≥ 28.8 mg/L 6.2 (2.1 - 17.1) 0.001 1.2 (0.3 - 5.5) 0.774
Bacteraemia
MASCC score < 21 6.9 (2.2 - 21.3) 0.001 1.7 (0.4 - 7.6) 0.506
PCT ≥ 0.34 mg/L 17.3 (4.5 - 67.0) < 0.001 10.1 (1.9 - 54.8) 0.008
LBP ≥ 40.7 mg/L 8.1 (2.6 - 25.6) < 0.001 1.6 (0.3 - 7.7) 0.574
OR - odd ratio. CI - confidence interval. MASCC - Multinational Association for Supportive Care in Cancer. PCT – procalcitonin. LBP - 
lipopolysaccharide binding protein. P < 0.05 was considered statistically significant.
Table 6. Univariate and multivariate regression to predict serious complications and bacteraemia
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similar to that chosen in our study (0.43 mg/L), and 
with a sensitivity and specificity of 80% and 76%, 
respectively (15). Interestingly, in Ahn et al. study, 
similarly to our results, PCT was an independent 
predictor for complications, with an OR of 5.76 (7). 
However, in Uys et al. study, none of the laboratory 
parameters, including PCT, was a significant pre-
dictor of resolution with or without complications 
and death (13). 
To our knowledge, no study has analysed the 
prognostic value of LBP in febrile neutropenia epi-
sodes. We have found that LBP had a prognostic 
value to predict serious complications significantly 
lower than that showed by the other tested bio-
marker, PCT. In other settings, LBP on admission 
failed to predict mortality in critically ill patients, 
with ROC AUC < 0.60, although in Villar et al. study, 
serial LBP serum measurements were associated 
with disease severity and outcomes (16,17).
In our study, we also evaluated the capacity of 
MASCC score and tested biomarkers to predict 
bacteraemia. Similarly to previous studies, the oc-
currence of serious complications was higher in 
bacteremic episodes (10). Procalcitonin was the 
variable which presented the highest ROC AUC 
(0.86) to predict bacteraemia, higher than MASCC 
score (ROC AUC: 0.74) and with a trend to be supe-
rior in comparison to LBP (ROC AUC: 0.76), proba-
bly due to the small size of study population and 
number of episodes of bacteraemia detected. Be-
sides, PCT was the only independent predictor for 
bacteraemia, with an OR of 10.1 for concentrations 
≥ 0.34 mg/L.
The role of MASCC score for prediction of bacte-
raemia has been recently evaluated by Ahn et al., 
who reported a ROC AUC slightly higher (0.82) 
than that found in our study (0.74) (6). Similar re-
sults have been recently reported by the same 
group, achieving ROC AUCs of 0.802 and 0.814 in 
derivation and validation sets, respectively (7). In 
the same study, a model including demographic, 
clinical and biochemical variables (PCT), achieved 
ROC AUCs of 0.86 in derivation set and of 0.87 in 
the validation set, respectively (7). 
The role of biomarkers to predict bacteraemia and 
other bloodstream infections has been widely 
studied in different settings, including patients 
presenting at ED and adult and child cancer pa-
tients with and without neutropenia (6,15,18-23). In 
a recent meta-analysis, Hoeboer et al. reported a 
ROC AUC of 0.78 to predict bacteraemia in pa-
tients with suspected infection presenting at an 
emergency department, decreasing to 0.71 in im-
munocompromised/neutropenic patients (24). In 
studies carried out in emergency departments in-
cluding only adult cancer patients with febrile 
neutropenia, ROC AUCs of PCT ranged from 0.75 
to 0.82, values slightly lower than that found in our 
study (ROC AUC: 0.86), and similar to those report-
ed in a general population presenting at an emer-
gency department, with sensitivities and specifici-
ties ranging from 60.5% to 71% and from 82% to 
82.3%, respectively (6,18-20,23). The optimal cut-
off in both studies was 0.5 mg/L, higher than that 
calculated in ours, 0.34 mg/L, with a sensitivity of 
81% and specificity of 80%. Some studies per-
formed in general population at emergency de-
partments recommend the use of a PCT concen-
tration of 0.1 mg/L to rule-out bacteraemia, with 
NPV ranging from 96.3% to 99.6% (18-20). Using 
this cut-off in our study, PCT achieved a NPV of 
100%. Similarly to previous studies, PCT was a 
strong independent predictor for bacteraemia in 
our study (6,23).
Fewer studies have evaluated the association be-
tween LBP levels and bacteraemia. Therefore, in 
Ratzinger et al. study, conducted in in-patients at 
standard care wards with suspected infection and 
systemic inflammatory response syndrome (SIRS), 
LBP showed a moderate ability to predict bacte-
raemia, with a ROC AUC of 0.63, similar to the ROC 
AUC reported by Gille-Johnson et al. to predict 
bacteraemia in an emergency department (ROC 
AUC: 0.65), but lower than that reported by Gaïni 
et al. in hospitalized patients with suspected infec-
tion, with a ROC AUC of 0.74 (25-27). The results re-
cently reported by Ratzinger et al. in adult in-pa-
tients with suspected sepsis and SIRS are of inter-
est, because they have reported that the prognos-
tic capacity of LBP for bacteraemia was significant-
ly lower in non-neutropenic SIRS patients (ROC 
AUC: 0.61) than in neutropenic SIRS patients (ROC 
AUC: 0.86), also higher than that calculated in our 
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study (ROC AUC: 0.76) (28). However, the mecha-
nism explaining these higher LBP levels in neutro-
penic patients has not been clearly elucidated. 
Only one prospective study has evaluated the pre-
dictive capacity of LBP for bacteraemia/clinical 
sepsis in the febrile neutropenia setting, but in a 
paediatric population, achieving a moderate per-
formance, with a ROC AUC of 0.65 (29).
We are aware of the limitations of our study. Firstly, 
this is a single-center study, which could limit the 
generalization of the results. Moreover, the num-
ber of episodes included was not high, which 
could imply a type-II error when making compari-
sons and the small number of detected outcomes 
does not allow robust conclusions to be drawn. 
Therefore, although recent studies have demon-
strated the influence of type of bacteria and infec-
tion foci on biomarker levels, we were not able to 
describe these differences in our population (30). 
However, our study population, although small, is 
a heterogeneous group, including patients with 
solid tumours and haematological cancers similar-
ly distributed as compared with other studies and 
with an incidence of serious complications similar 
to that reported in previous studies (7).
In conclusion, our results suggest that the meas-
urement of an easily measurable and with a short 
turn-around-time biomarker, PCT, is a useful tool 
for risk-stratification of cancer patients with febrile 
neutropenia, with a similar prognostic capacity as 
MASCC score, and higher than that found for the 
other tested biomarker, LBP. Besides, in these pa-
tients, PCT is a useful marker to rule-out bacterae-
mia. Further larger studies about the safety and ef-
ficacy of using PCT as a single prognostic tool or in 
combination with risk index scores are required.
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